AU502164B2 - Pharmaceutical composition containing 2, 6-diisopropylphenol - Google Patents

Pharmaceutical composition containing 2, 6-diisopropylphenol

Info

Publication number
AU502164B2
AU502164B2 AU79536/75A AU7953675A AU502164B2 AU 502164 B2 AU502164 B2 AU 502164B2 AU 79536/75 A AU79536/75 A AU 79536/75A AU 7953675 A AU7953675 A AU 7953675A AU 502164 B2 AU502164 B2 AU 502164B2
Authority
AU
Australia
Prior art keywords
diisopropylphenol
pharmaceutical composition
composition containing
pharmaceutical
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU79536/75A
Other languages
English (en)
Other versions
AU7953675A (en
Inventor
J. B. & James. R Glen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Imperial Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Chemical Industries Ltd filed Critical Imperial Chemical Industries Ltd
Publication of AU7953675A publication Critical patent/AU7953675A/en
Application granted granted Critical
Publication of AU502164B2 publication Critical patent/AU502164B2/en
Assigned to ZENECA LIMITED reassignment ZENECA LIMITED Alteration of Name(s) in Register under S187 Assignors: IMPERIAL CHEMICAL INDUSTRIES LIMITED
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB Alteration of Name(s) in Register under S187 Assignors: ZENECA LIMITED
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU79536/75A 1974-03-28 1975-03-26 Pharmaceutical composition containing 2, 6-diisopropylphenol Ceased AU502164B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1373974A GB1472793A (en) 1974-03-28 1974-03-28 Pharmaceutical compositions
GBGB13739 1974-03-28

Publications (2)

Publication Number Publication Date
AU7953675A AU7953675A (en) 1976-09-30
AU502164B2 true AU502164B2 (en) 1979-07-12

Family

ID=10028495

Family Applications (1)

Application Number Title Priority Date Filing Date
AU79536/75A Ceased AU502164B2 (en) 1974-03-28 1975-03-26 Pharmaceutical composition containing 2, 6-diisopropylphenol

Country Status (22)

Country Link
US (2) US4056635A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS50154410A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU502164B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE827290A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1038764A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE2513797C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK128675A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DO (1) DOP1980002892A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI750941A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2265357B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB1472793A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK34380A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE40839B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL46899A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KE (1) KE3052A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY8100111A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (2) NL183079C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO751076L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ177023A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH13553A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (1) SE7503542L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA751806B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU223343B1 (hu) * 1991-05-20 2004-06-28 Novartis Ag. Allil-amin-származékot tartalmazó gyógyászati készítmények és eljárás azok előállítására
US6005001A (en) * 1991-05-20 1999-12-21 Novartis Ag (Formerly Sandoz Ag) Pharmaceutical composition
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US20020173547A1 (en) 1994-03-22 2002-11-21 Jones Christopher Buchan Pharmaceuticals compositions
US5731356A (en) * 1994-03-22 1998-03-24 Zeneca Limited Pharmaceutical compositions of propofol and edetate
MY113046A (en) * 1994-03-22 2001-11-30 Astrazeneca Uk Ltd Pharmaceutical compositions
GB9405593D0 (en) * 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
IT1269977B (it) 1994-07-01 1997-04-16 Archimica Spa Purificazione del propofol
IT1270093B (it) 1994-09-28 1997-04-28 Zambon Spa Processo per la purificazione di 2,6-diisopropilfenolo
CN1106192C (zh) * 1995-03-17 2003-04-23 曾尼卡有限公司 含2,6－二异丙基苯酚和乙二胺四乙酸盐的水包油型乳液
CN100512877C (zh) * 1995-03-17 2009-07-15 曾尼卡有限公司 无菌医药组合物
AU6708096A (en) * 1995-09-18 1997-04-09 Vesifact Ag Propofol nanodispersions
US6576264B1 (en) 1995-10-17 2003-06-10 Skyepharma Canada Inc. Insoluble drug delivery
US5637625A (en) * 1996-03-19 1997-06-10 Research Triangle Pharmaceuticals Ltd. Propofol microdroplet formulations
US7255877B2 (en) 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
CH692322A5 (it) * 1997-05-26 2002-05-15 Westy Ag Formulazione iniettabile limpida di Propofol.
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
DE19757224A1 (de) 1997-12-22 1999-07-01 Bayer Ag Verfahren und Vorrichtung zur in-situ-Formulierung einer Arzneistofflösung zur parenteralen Applikation
JP2002502811A (ja) * 1998-02-10 2002-01-29 サイコール・インコーポレイテッド 亜硫酸塩を含有するプロポフォール組成物
ATE241363T1 (de) * 1998-02-11 2003-06-15 Rtp Pharma Corp Ungesättigte fettsäure und steroide enthaltende kombinationspräparate zur behandlung von entzündungen
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
DE69914742T2 (de) 1998-05-29 2004-11-25 Skyepharma Canada Inc., Verdun Gegen hitzeeinwirkung geschützte mikropartikel und verfahren zur terminalen dampfsterilisation derselben
EP1105096B1 (en) 1998-08-19 2003-10-29 Skyepharma Canada Inc. Injectable aqueous dispersions of propofol
US6150423A (en) * 1998-10-15 2000-11-21 Phoenix Scientific, Inc. Propofol-based anesthetic and method of making same
US6028108A (en) * 1998-10-22 2000-02-22 America Home Products Corporation Propofol composition comprising pentetate
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
HUP0105089A3 (en) 1998-11-20 2002-09-30 Skyepharma Canada Inc Compositions containing the active ingredient in form dispersible phospholipid stabilized microparticles
US6177477B1 (en) * 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6100302A (en) 1999-04-05 2000-08-08 Baxter International Inc. Propofol formulation with enhanced microbial characteristics
KR100410937B1 (ko) * 1999-06-21 2003-12-18 건일제약 주식회사 프로포폴을 함유하는 혈관주사용 마취제 조성물
GB2359747B (en) * 2000-02-29 2002-04-24 Maelor Pharmaceuticals Ltd Anaesthetic formulations
KR100386397B1 (ko) * 2000-04-19 2003-06-02 센츄론(주) 투명한 프로포폴 주사제
US6682761B2 (en) 2000-04-20 2004-01-27 Rtp Pharma, Inc. Water-insoluble drug particle process
EP2036540A3 (en) 2000-06-16 2009-12-16 Jagotec AG Improved injectable dispersions of propofol
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE60137943D1 (de) 2000-08-31 2009-04-23 Jagotec Ag Gemahlene partikel
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US7037528B2 (en) * 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
ATE357216T1 (de) * 2001-02-22 2007-04-15 Jagotec Ag Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
JP4127757B2 (ja) * 2001-08-21 2008-07-30 株式会社エヌ・ティ・ティ・ドコモ 無線通信システム、通信端末装置、及びバースト信号送信方法
GB0120702D0 (en) * 2001-08-24 2001-10-17 Maelor Pharmaceuticals Ltd Anaesthetic formulations
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
EP1429749A2 (en) 2001-09-26 2004-06-23 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
EP1430017A2 (en) 2001-09-26 2004-06-23 Theravance, Inc. Substituted phenol compounds useful for anesthesia and sedation
GB0124071D0 (en) * 2001-10-08 2001-11-28 Kbig Ltd Improvement in the administration of high boiling point aneasthetics
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
NZ533536A (en) * 2001-12-28 2006-11-30 Mgi Gp Inc Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol such as O-phosphonooxymethyl propofol
JP3931680B2 (ja) * 2002-02-18 2007-06-20 株式会社日本自動車部品総合研究所 車両の直進判別装置
US7550155B2 (en) * 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
BR0313060A (pt) * 2002-07-29 2005-06-28 Transform Pharmaceuticals Inc Composições farmacêuticas aquosas de 2,6-diisopropilfenol
US20040220283A1 (en) * 2002-07-29 2004-11-04 Transform Pharmaceuticals, Inc. Aqueous 2,6-diisopropylphenol pharmaceutical compositions
EP1555976A4 (en) * 2002-10-29 2007-11-14 Transform Pharmaceuticals Inc Propofol with cysteine
AU2003275360A1 (en) * 2002-10-29 2004-05-25 Transform Pharmaceuticals, Inc. Aqueous 2,6-diisopropylphenol pharmaceutical compositions
RU2343145C2 (ru) * 2002-11-26 2009-01-10 Маруиси Фармасьютикал Ко., Лтд. Производные изоиндолина
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US8476010B2 (en) 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
US8546453B2 (en) * 2003-08-14 2013-10-01 Rensheng Zhang Propofol compositions and methods for reducing pain associated with propofol injection
ITMI20032054A1 (it) * 2003-10-22 2005-04-23 Monteres S R L Processo per la preparazione di sospensioni farmaceutiche da inalare.
US7112561B2 (en) 2003-12-08 2006-09-26 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for insulin treatment
US20050196416A1 (en) * 2004-02-05 2005-09-08 Kipp James E. Dispersions prepared by use of self-stabilizing agents
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
CA2608930A1 (en) * 2005-06-14 2006-12-28 Baxter International Inc. Pharmaceutical formulations for minimizing drug-drug interactions
WO2007143038A1 (en) * 2006-05-30 2007-12-13 Trustees Of Columbia University In The City Of New York Method of mediating airway smooth muscle construction due to airway irritation
WO2008008492A2 (en) * 2006-07-13 2008-01-17 University Of Iowa Research Fdtn. Hydrofluoroalkyl phenols having anesthetic properties
WO2008080047A2 (en) * 2006-12-23 2008-07-03 Baxter International Inc. Magnetic separation of fine particles from compositions
JP5651009B2 (ja) 2007-05-09 2015-01-07 ソウッド ヘルスケア エルエルシー 治療用化合物
RU2470907C2 (ru) * 2007-05-09 2012-12-27 Сигничер Терапьютикс, Инк. Терапевтические соединения
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US20090198145A1 (en) * 2008-02-06 2009-08-06 Chow Harrison Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
US20180022698A1 (en) 2014-10-16 2018-01-25 The Board Of Trustees Of The Leland Stanford Junior University Novel methods, compounds, and compositions for anesthesia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2104412A (en) * 1931-12-29 1938-01-04 Standard Oil Dev Co Alkyl phenols
GB831071A (en) 1956-04-26 1960-03-23 British Schering Ltd Analgesic compounds
GB803080A (en) 1956-07-06 1958-10-15 Scient Oil Compounding Co Inc Bacteriostatic compositions
US2966442A (en) * 1956-09-20 1960-12-27 American Home Prod Antibiotic compositions
US3476838A (en) * 1958-12-04 1969-11-04 Ethyl Corp Di(2,6-diisopropylphenyl) mono halo phosphite or (thio) phosphate
US3067106A (en) * 1959-04-07 1962-12-04 Foundation For Prosthetic Res Skin treating method and composition

Also Published As

Publication number Publication date
SE7503542L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1975-09-29
NL7503696A (nl) 1975-09-30
IL46899A0 (en) 1975-06-25
FI750941A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1975-09-29
IL46899A (en) 1978-03-10
HK34380A (en) 1980-07-01
MY8100111A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1981-12-31
JPS50154410A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1975-12-12
IE40839B1 (en) 1979-08-29
AU7953675A (en) 1976-09-30
DOP1980002892A (es) 1989-10-04
FR2265357B1 (fr) 1978-08-04
BE827290A (fr) 1975-09-29
CA1038764A (en) 1978-09-19
IE40839L (en) 1975-09-28
NL183079C (nl) 1988-07-18
NO751076L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1975-09-30
KE3052A (en) 1980-06-27
NZ177023A (en) 1984-09-28
GB1472793A (en) 1977-05-04
ZA751806B (en) 1976-02-25
DE2513797C2 (de) 1987-07-30
US4452817A (en) 1984-06-05
NL930084I1 (nl) 1993-09-16
DK128675A (de) 1975-09-29
FR2265357A1 (fr) 1975-10-24
US4056635A (en) 1977-11-01
PH13553A (en) 1980-06-26
NL930084I2 (nl) 1994-10-17
DE2513797A1 (de) 1975-10-09

Similar Documents

Publication Publication Date Title
AU502164B2 (en) Pharmaceutical composition containing 2, 6-diisopropylphenol
AU515341B2 (en) Pharmaceutical composition
CA1033750A (en) 5-methyl-isoflavone-derivatives, process for the preparation thereof and compositions containing the same
AU487061B2 (en) Pharmaceutical compositions
AU497120B2 (en) Polyhydroxy-alkyl-3,5-disubstituted-2, 4,6-triiodo-carbanilates
AU508191B2 (en) Pharmaceutical composition
AU506178B2 (en) Anaesthetic composition
IL49344A (en) 2-substituted-7-halo-1,8-maphthyridine compounds,processesfor preparing the same and pharmaceutical compositions containing the same
AU498671B2 (en) 1-aryl-2-oxo-hexahydro-2,4,5,6,7,7a-indoles
CA1026674A (en) Anesthetic composition
ZA757067B (en) Pharmaceutical compositions comprising substituted 4,6-dihydroxy-2h-pyran-2-ones
AU488718B2 (en) Pharmaceutical, composition
CA1029373A (en) 1,2,4-dithiaaz-3-enes
CA1032169A (en) 1,2,4-triazolidin-3-ones
AU8102375A (en) Pharmaceutical, composition
AU484787B2 (en) Substituted 1, 3-diphenyltriazines and pharmaceutical compositions thereof
AU507862B2 (en) Novel 2,3-dioxopiperazine derivatives
AU8102475A (en) Pharmaceutical composition
AU492255B2 (en) Pharmaceutical compositions
AU8130275A (en) Substituted 1, 3-diphenyltriazines and pharmaceutical compositions thereof
CA1022302A (en) Flame-sprayable composition
AU500951B2 (en) 1,3-bis(tert-butylpithio)-2-dimethylamino-propane
AU490114B2 (en) i, 2, 4-TRIAZOLIDIN-3-ONES
AU8474775A (en) Pharmaceutical compositions
AU488834B2 (en) Local anesthetic composition

Legal Events

Date Code Title Description
PC Assignment registered

Owner name: ASTRAZENECA AB

Free format text: FORMER OWNER WAS: ZENECA LIMITED

MK14 Patent ceased section 143(a) (annual fees not paid) or expired